by Kinnate Biopharma | Sep 12, 2020
This is a placeholder. It's hidden from the grid/chart , but necessary to display the filter option until real projects have this category. Keep the category "Hidden"...
by Kinnate Biopharma | Sep 12, 2020
Our FGFR program, KIN-3248 is a small-molecule kinase inhibitor that target cancer-associated alterations in FGFR2 and FGFR3 genes, which are among the most commonly identified oncogenic drivers detected in solid tumor cancers. KIN-3248 aims to address the primary...
by Kinnate | Sep 12, 2020
Our lead RAF program, KIN 2787 is a small molecule kinase inhibitor targeting specific classes of BRAF kinase alterations (Class II and Class III) that characterize subsets of melanoma, lung cancer, and other solid tumors. As a pan-RAF kinase inhibitor, KIN-2787...
by Kinnate Biopharma | Sep 12, 2020
Our lead RAF program, KIN 2787 is a small molecule kinase inhibitor targeting specific classes of BRAF kinase alterations (Class II and Class III) that characterize subsets of melanoma, lung cancer, and other solid tumors. As a pan-RAF kinase inhibitor, KIN-2787...
Recent Comments